We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$961M
AUM Growth
+$374M
Cap. Flow
-$4.74M
Cap. Flow %
-0.49%
Top 10 Hldgs %
44.93%
Holding
194
New
69
Increased
29
Reduced
39
Closed
48

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$24.6M
2
AGN
Allergan plc
AGN
+$24.2M
3
MRK icon
Merck
MRK
+$22.3M
4
AMGN icon
Amgen
AMGN
+$17.6M
5
ENDP
Endo International plc
ENDP
+$17.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$33.6M
2
SHPG
Shire pic
SHPG
+$20.7M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.2M
4
BIIB icon
Biogen
BIIB
+$11.8M
5
ISRL
Isramco Inc
ISRL
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 53.73%
2 Technology 2.61%
3 Industrials 1.8%
4 Consumer Discretionary 1.51%
5 Utilities 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENTA icon
151
Enanta Pharmaceuticals
ENTA
$366M
– –
-40,000
Closed -$2.03M
ESLT icon
152
Elbit Systems
ESLT
$37.9B
– –
-144,759
Closed -$8.85M
GILD icon
153
CALL
Gilead Sciences
GILD
$162B
– –
-394,200
Closed -$3.95M
GSK icon
154
CALL
GSK
GSK
$104B
– –
-233,040
Closed -$7K
GSK icon
155
GSK
GSK
$104B
– –
-78,560
Closed -$4.2M
ICL icon
156
ICL Group
ICL
$6.53B
– –
-40,116
Closed -$291K
IMUX icon
157
Immunic
IMUX
$190M
– –
-205
Closed -$2.04M
ITRN icon
158
Ituran Location and Control
ITRN
$1.09B
– –
-168,203
Closed -$3.71M
LLY icon
159
Eli Lilly
LLY
$1.02T
– –
-87,100
Closed -$6.01M
LRMR icon
160
Larimar Therapeutics
LRMR
$397M
– –
-6,008
Closed -$2.22M
NICE icon
161
Nice
NICE
$5.79B
– –
-39,652
Closed -$2.01M
NVAX icon
162
Novavax
NVAX
$1.2B
– –
-77
Closed -$9K
PRQR icon
163
ProQR Therapeutics
PRQR
$243M
– –
-130,000
Closed -$2.82M
SRPT icon
164
Sarepta Therapeutics
SRPT
$1.57B
– –
-175,000
Closed -$2.53M
TLPH icon
165
Talphera
TLPH
$66.4M
– –
-5,000
Closed -$673K
VRTX icon
166
Vertex Pharmaceuticals
VRTX
$121B
– –
-30,000
Closed -$3.56M
WIX icon
167
WIX.com
WIX
$2.3B
– –
-59,108
Closed -$1.24M
XLB icon
168
PUT
State Street Materials Select Sector SPDR ETF
XLB
$8.5B
– –
-100,000
Closed -$116K
XLF icon
169
State Street Financial Select Sector SPDR ETF
XLF
$56.7B
– –
-239,221
Closed -$5.19M
EIGR
170
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-335
Closed -$2.94M
ACOR
171
DELISTED
Acorda Therapeutics
ACOR
– –
-659
Closed -$3.23M
DRNA
172
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-176,802
Closed -$2.91M
MNK
173
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-90,940
Closed -$9.01M
BCOM
174
DELISTED
B Communications Ltd
BCOM
– –
-134,174
Closed -$2.42M
MLNX
175
DELISTED
Mellanox Technologies, Ltd.
MLNX
– –
-12,517
Closed -$535K
4 5 6
7
8

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sphera Funds Management held 194 positions worth $961M, up 64% from $587M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management's Q1 2015 filing shows 69 new, 29 increased, 39 reduced and 48 closed positions. Its largest new stake was AbbVie: 407,000 shares worth $23.8M. The largest sale was Novartis, an estimated $33.6M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 63% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q1 2015 buy was AbbVie: 407,000 shares worth $23.8M.
  • Sphera Funds Management added most to Allergan plc in Q1 2015, an estimated $24.2M increase.
  • Sphera Funds Management's biggest Q1 2015 reduction was Novartis, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q1 2015, selling an estimated $18.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $961M portfolio in Q1 2015.
  • Sphera Funds Management opened 69 new positions and closed 48 in Q1 2015.
  • Sphera Funds Management's portfolio value rose 64% quarter-over-quarter to $961M.

Based on Sphera Funds Management's 13F filing for Q1 2015, filed 11 May 2015.